Article

The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma

2019-09-16

Abstract excerpt

<h4>Rationale</h4> High-grade serous ovarian carcinoma (HGSOC) is the deadliest of gynecological cancers due to high rate of recurrence and acquired chemoresistance. Mutation and activation of the RAS/MAPK pathway has been linked to cancer cell proliferation and therapeutic resistance in numerous cancers. While RAS mutations are not commonly observed in HGSOC, less is known about downstream pathway activation. We...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9a093baa-e61b-513e-938a-545b394d85da
DOI: 10.1101/772061

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinomaDOI 10.1101/772061Read

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK InhibitionSemantic proximity Read

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity Read

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapySemantic proximity Read

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity Read

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.Semantic proximity Read

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.Semantic proximity Read

Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.Semantic proximity Read

Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma identifies clinically distinct disease subtypesSemantic proximity Read